Medicación estimulante para el TDAH en el entorno escolar: Metilfenidato 30/70
PDF

Palabras clave

TDAH
Trastorno por Déficit de Atención e Hiperactividad

Cómo citar

Pelaz, A., Mardomingo, M. J., Herreros, O., Rodríguez Hernández, P. J., Gastaminza, X., Muñoz, A. M., & Plaza, S. (2013). Medicación estimulante para el TDAH en el entorno escolar: Metilfenidato 30/70. Revista De Psiquiatría Infanto-Juvenil, 30(1), 16-26. Recuperado a partir de https://aepnya.eu/index.php/revistaaepnya/article/view/259

Resumen

El Trastorno por Déficit de Atención e Hiperactividad (TDAH) es uno de los trastornos psiquiátricos más frecuentes en la infancia, con una prevalencia global acumulada de aproximadamente el 5 %. Se caracteriza por la presencia de síntomas como la inatención, impulsividad e hiperactividad. Como consecuencia de estos, los niños con TDAH muestran dificultades en centrar la atención, en el control de sus impulsos y en modular su comportamiento desde edades muy tempranas. La evidencia clínica sugiere que, a menos que se alcance un mínimo de competencia social hacia los 8 años de edad, estos niños tendrán una alta probabilidad de tener dificultades sociales a lo largo de su vida. El tratamiento del TDAH consiste en varias estrategias combinadas (tratamiento multimodal) de las cuales la farmacoterapia ocupa un lugardestacado según las diferentes guías de práctica clínica. En referencia al entorno escolar, los objetivos principales del tratamiento del TDAH se centran en adaptar al niño a los requerimientos sociales y académicos mediante la disminución del impacto de los síntomas nucleares. El metilfenidato para el TDAH ha demostrado su eficacia con un perfil de seguridad adecuado. Su perfil de liberación está correlacionado con su eficacia clínica y por tanto un perfil de liberación que cubra de manera homogénea las 8 horas como el metilfenidato 30/70 es eficaz durante toda la jornada escolar.

PDF

Referencias

Polanczyk, de Lima, Horta, Biederman, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164 (6): 942-8.

American Psychiatric Association [DSM-IV-TR], 2000.

CIE-10: ICD-10 copyright © 1992 by World Health Organization.

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. MTA cooperative Group. Arch. Gen Psychiatry 1999: 1088-1096.

Barkley, R. A. (2006). Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed.).

Guilford Press, Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998; 279: 1100–1107.

Cardo E, Servera M, Llobera J. Estimation of the prevalence of attention defi cit hyperactivity disorder among the standard population on the island of Majorca. Rev Neurol. 2007 1; 44 (1): 10-4.

Benjumea P, Mojarro MA. Trastornos hipercinéticos: estudio epidemiológico en doble fase de una población sevillana. Anales de Psiquiatría. 1993; 9 (7): 306-11.

Scheffler RM, Brown TT, Fulton BD, Hinshaw SP, Levine P, Stone S. Positive Association Between Attention-Deficit/ Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School. Pediatrics 2009; 123: 1273.

Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Ministerio Sanidad, Política Social e Igualdad. 2010.

National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Great Britain: The British Psychological Society and The Royal College of Psychiatrist; 2009.

Mannuzza S, Klein RG, Bessler A, Malloy P, Hynes ME. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36:1222–1227.

CHILD MENTAL HEALTH AND HUMAN CAPITAL ACCUMULATION: THE CASE OF ADHD Janet Currie Mark Stabile http://www.nber.org/papers/w10435.

McGee, R. Williams, S. Feehan, M. Attention deficit disorder and age of onset of problem behaviors. Journal of Abnormal Child Psychology 1992; 20: 487–502.

McGee, R., Prior, M., Williams, S. The long-term significance of teacher-rated hyperactivity and reading ability in childhood: findings from two longitudinal studies. The Journal of Child Psychology and Psychiatry 2002; 43: 1004–1017.

School Functioning of Students With ADHD: Du-Paul School Psychology Review,2007, Volume 36, No. 2, pp. 183–194.

Blair, C.,Diamond, A.. Biological processes in prevention and intervention: The promotion of selfregulation as a means of preventing school failure. Development and Psychopathology (2008), 20(3), 899-911.

Duncan, G. J., Dowsett, C. J., Claessens, A., Magnuson, K., Huston, A. C., Klebanov, P., et al. (2007). School readiness and later achievement. Dev Psychol, 43(6), 1428-1446.)

Loe, I.M.,Feldman, H.M. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. 2007 Jul;32(6):643-54. Epub 2007 Jun 14

Barry, R. J., Clarke, A. R., McCarthy, R., Selikowitz, M. EEG coherence in attention-deficit/ hyperactivity disorder: a comparative study of two DSM-IV types. Clin Neurophysiol, (2002);113(4), 579-585.,

Biederman, J., Faraone, S., Milberger, S., Guite, J., Mick, E., Chen, L., et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996., 53(5), 437-46)

Barkley, R.A., Fischer, M, Edelbrock, C.S., & Smallish, L. (1990). The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. Jul;29(4):546-57)

Mannuzza, S., Klein, R.G., Bessler, A., Malloy, P. LaPadula, M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry, 1993; 50(7), 565-76.)

Hinshaw, S.P. (1992). Academic underachievement, attention deficits, and aggression: comorbidity and implications for intervention. J Consult Clin Psychol, 60(6), 893-903.

Rapport, M.D, Scanlan, S.W., Denney, C.B. Attention-deficit/hyperactivity disorder and scholastic achievement: a model of dual developmental pathways. J Child Psychol Psychiatry, 1999; 40(8), 1169-1183).

Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M. Cost-Effectiveness of ADHD Treatments: Findings from the Multimodal Treatment Study of Children With ADHD. Am J Psychiatry 2005; 162: 1628-1636.

Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ: Modifiers of long term school outcomes for children with Attention- deficit/Hyperactivity Disorder: Does treatment with stimulant medication make a difference? Results from a population- based study. J Develop Behav Pediatr 2007; 28: 274–287.

Powers RL, Marks DJ, Miller CJ, Newcorn JH, Halperin JM. Stimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder Moderates Adolescent Academic Outcome. J Child Adolesc Psychopharmacol. 2008; 18 (5): 449-59.

Zoëga H, Rothman KJ, Huybrechts KF, Ólafsson Ö, Baldursson G, Almarsdóttir AB et al. A Population- Based Study of Stimulant Drug Treatment of ADHD and Academic Progress in Children. Pediatrics. 2012; 130 (1): e53-62.

Loe IM, Feldman HM. Academic and Educational Outcomes of Children With ADHD. J Pediatr Psychol. 2007; 32 (6): 643-54.

Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001; 9 (2): 163-75.

Richard M. Scheffler, Timothy T. Brown, Brent D. Fulton, Stephen P. Hinshaw, Peter Levine, Susan Stone. Positive Association Between Attention-Deficit/Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School. Pediatrics. 2009; 123 (5): 1273-9.

Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Blader et al. Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD. Pediatrics 2010; 126: e796.

Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr. 1995; 16 (3): 167-76).

Gadow KD, Nolan EE, Sverd J, Sprafkin J, Paolicelli L. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry. 1990; 29 (5): 710-8.

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder— first upgrade. Eur Child Adolesc Psychiatry 2004; 13(Suppl1): 17–30.

NICE clinical guideline 72. Attention deficit hyperactivity disorder. www.nice.org.uk/CG072.

Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry 2004; 161, 1173–1180.

Agencia Española del Medicamento y Producto Sanitario (AEMPS). http://www.aemps.gob.es/

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006; 15 (8): 476-95.

Wigal, Sanchez, DeCory, D’imperio, Swanson. Selection of the optimal doses ratio for a controlled-delivery formulation of methylphenidate. The journal of applied research 2003; 3 (1).

Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M. Comparison of the clinical efficacy of twice-daily Ritalin and oncedaily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. Eur Child Adolesc Psychiatry. 2006; 15 (8): 450-9.

M.A. González, H.S. Pentikis, N. Anderl, M.F. Ben e dict, H.H. DeCory, S.J. Hirshey Dirksen et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther. 2002; 40 (4): 175-84.

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004; 113 (3 Pt 1): e206-16.

Rothenberger A, Döpfner M. Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherente. Eur Child Adolesc Psychiatry. 2011; 20 Suppl 2: S235-42.

Descargas

Los datos de descarga todavía no están disponibles.